Amgen Hits Primary Endpoint In Sjögren's Trial, But Approval Filing Awaits Another Trial Data
In brief
Amgen’s Phase 3 trial hit its primary goal, but a second positive study is still needed before FDA filing.
ClearTape summarizes context in-app. For the full publisher article, use Read original source above.